"Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer." by Reshma Mahtani

Article

Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer.

Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting (2017)

Reshma Mahtani, Baptist Health South Florida
V. Gadi
T. Operna
H. Soifer
B. Schroeder
C. Schnabel
L. Schwartzberg

Link

Disciplines

Medicine and Health Sciences

Publication Date

2017

Citation Information

Reshma Mahtani, V. Gadi, T. Operna, H. Soifer, et al.. "Clinical Utilization of Breast Cancer Index (BCI) for Late Recurrence Risk Assessment and Prediction of Extended Endocrine Therapy (EET) Benefit in Early Stage HR+ Breast Cancer." Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting Vol. 35 Iss. 15 Suppl. (2017)
Available at: http://works.bepress.com/reshma-mahtani/15/